Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Study of Pacritinib in Vacuoles, E1 Ubiqutin-activating Enzyme, X-linked, Autoinflammatory, Somatic (VEXAS) Syndrome

NCT06538181 is registered in ClinicalTrials.gov with Washington University School of Medicine as lead sponsor.

NCT NCT06538181
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06538181 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Study of Pacritinib in Vacuoles, E1 Ubiqutin-activating Enzyme, X-linked, Autoinflammatory, Somatic (VEXAS) Syndrome
Lead sponsor
Washington University School of Medicine
Phase
Phase 1
Overall status
Recruiting
Start date
February 13, 2025
Completion date
February 28, 2029
Enrollment
15 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

e1 ubiqutin-activating enzyme, x-linked, autoinflammatory, somatic syndrome, vexas, vexas syndrome